A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

Completed · Phase 1

Conditions studied: Healthy

In brief

The purpose of this study is to evaluate the Plasma Pharmacokinetics and Safety of AC 170 0.24% in Healthy, Adult Subjects when used twice daily for one week.

Key facts

Study ID

NCT02173249

Run by

Aciex Therapeutics, Inc.

People needed

11

Starts

2014-06-01

Expected to finish

2014-08-01

Last updated by the study team

2017-09-14

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• at least 18 and no older than 55 years of age
• be able to self-administer eye drops or have a parent/legal guardian available for this purpose
• have blood and urine analysis within normal limits
• have ocular health within normal limits

You may not qualify if…

• known contraindications or sensitivities to the study medication or its components
• have any active systemic or ocular disorder (other than refractive disorder)
• have inability to comply with controlled diet
• have used prescription or non prescription drugs within washout period and throughout study
• have used alcohol or tobacco within the washout period

Where it is running

• Andover Eye Associates — Andover, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.